Skip to main content
. 2021 Sep 15;148(6):1481–1492.e2. doi: 10.1016/j.jaci.2021.09.008

Fig 2.

Fig 2

SARS-CoV-2–specific ELISPOT assay. PBMCs were isolated from convalescent patients at 1 year postinfection and stimulated with medium, SARS-CoV-2 peptide pool, or PHA for 18 to 24 hours. Then, the number of SARS-CoV-2–specific T cells was measured by IFN-γ ELISPOT assay. A, Representative graphs showing the numbers of SARS-CoV-2–specific T cells in HCs and convalescent patients with COVID-19 with moderate or severe disease. B, The numbers of SARS-CoV-2–specific T cells (SFCs/2.5 × 105 PBMCs) in different groups were expressed as median with IQR. C, Correlation between SARS-CoV-2–specific T-cell numbers and nAb titers. D, Correlation between SARS-CoV-2–specific T-cell numbers and anti-RBD antibody levels. HC, Healthy control; IQR, interquartile range; SFC, spot-forming cell. ∗∗P < .01.